GSK to Acquire 35Pharma for Under $1B
GlaxoSmithKline (GSK) announced the acquisition of privately held 35Pharma, a developer of a pulmonary arterial hypertension drug. The cash deal is valued at just under $1 billion, expanding GSK’s pipeline in respiratory and immunology.
Slate Medicines Secures $130M Series A Funding Led by RA Capital, Forbion and Foresite Capital
Slate Medicines, a North Carolina‑based biotech startup, announced a $130 million Series A round to fund development of its PACAP‑blocking migraine antibody SLTE‑1009. The round was led by RA Capital, Forbion and Foresite Capital, with participation from an undisclosed biotech investor. The...
Brainomix Raises £4.8m in Series C Extension, Bringing Total to £18.8m
Oxford‑based AI imaging firm Brainomix announced a £4.8 million extension to its Series C round, taking the total to £18.8 million. The new funding, led by existing investors Parkwalk Advisors and Hostplus (via the IP Group Hostplus Innovation Fund) and joined by new...
Centauri Therapeutics Raises £30m Series A Round
Centauri Therapeutics, a Cheshire‑based biotech, announced a £30 million Series A funding round to advance its antimicrobial immunotherapy programme, including a £6 million investment from AMR Action Fund. The capital will support the completion of Phase I trials for its lead candidate...
Beam Therapeutics Secures $500M Strategic Financing From Sixth Street
Beam Therapeutics announced a $500 million strategic financing agreement with Sixth Street to fund the potential launch of its sickle cell disease therapy and advance its BEAM‑304 program for phenylketonuria. The financing will support development of the gene‑editing platform and...
Guardant Health Acquires MetaSight Diagnostics for $59M Upfront
Guardant Health announced the acquisition of MetaSight Diagnostics for $59 million in upfront cash, with up to $90 million in additional contingent payments tied to commercial performance and regulatory approvals. The deal expands Guardant’s multi‑disease detection pipeline beyond oncology, adding MetaSight’s mass‑spectrometry...
Gilead Sciences to Acquire Arcellx for up to $7.8B
Gilead Sciences announced it will acquire biotech Arcellx in a cash deal valued at up to $7.8 billion, paying $115 per share plus a contingent $5 per share based on future sales. The acquisition aims to strengthen Gilead's cancer drug pipeline,...
Resurrect Bio Secures $8.1M in Series A Initial Close
Resurrect Bio announced an $8.1 million initial close of its Series A financing round, marking the first tranche of capital for the biotech startup. The round aims to fund the company's next phase of research and development.
Candel Therapeutics Secures $100M Royalty Funding From RTW Investments
Candel Therapeutics announced a $100 million royalty financing agreement with RTW Investments to support the launch of its gene therapy Aglatimagene Besadenovec for localized prostate cancer. The deal grants RTW a capped, tiered royalty on U.S. net sales, contingent on...
Altesa Raises $75M for Oral Respiratory Med
Altesa announced a $75 million fundraising round to develop its oral respiratory medication. The capital will support further clinical development and commercialization efforts.
Altesa BioSciences Secures $75M Series B Funding
Altesa BioSciences announced a $75 million Series B financing round, bolstering its pipeline in the biotech sector. The new capital will support the company's research and development initiatives and accelerate growth.
Gilead to Acquire Genhouse in $1.5B+ Deal to Accelerate Synthetic Lethality
Gilead Sciences announced a deal to acquire Genhouse for over $1.5 billion, aiming to strengthen its synthetic lethality oncology pipeline. The acquisition brings Genhouse’s portfolio of synthetic lethality drug candidates and technology into Gilead’s pipeline, underscoring its commitment to precision oncology.
Eli Lilly Pays $100M for Rights to CSL’s Clazakizumab
Eli Lilly announced it will pay $100 million to CSL Limited for the rights to the IL‑6‑blocking antibody clazakizumab, with CSL retaining rights for cardiovascular prevention in end‑stage kidney disease patients. The deal includes an upfront payment and potential milestone and...
Peptris Raises ₹70 Crore to Scale AI-Led Drug Discovery Pipeline
Peptris, an AI-driven drug discovery startup, announced a fresh funding round of ₹70 crore to expand its pipeline and accelerate preclinical programs. The capital will be used to scale its AI-led platform and advance its drug discovery efforts. The raise...
Korsana Raises $150M in Series A to Develop Next‑gen Alzheimer’s Antibody
Korsana, a biotech focused on Alzheimer’s disease, announced a $150 million Series A funding round to advance its next‑generation amyloid‑targeting antibody. The capital will fund clinical development and expansion of its pipeline. Investor identities were not disclosed.
Sensei Biotherapeutics Acquires Faeth Therapeutics in Stock-for-Stock Deal, Raises $200M
Sensei Biotherapeutics announced the acquisition of Faeth Therapeutics in a stock-for-stock transaction, consolidating the two biotech firms. Concurrently, Sensei raised $200 million in a private placement to fund the development of PIKTOR, its multi-node PI3K/AKT/mTOR inhibitor. The acquisition price was...
Unnatural Products Secures $1.8B Cardio Pact with Novartis
Biotech firm Unnatural Products announced a $1.8 billion partnership with pharmaceutical giant Novartis to develop cardiovascular therapies. The agreement includes a corporate investment from Novartis, marking a significant funding boost for Unnatural Products.
Intrinsic Foundries Secures Rs 12 Cr Seed Funding Led by Transition VC
Intrinsic Foundries, a carbon‑to‑value biomanufacturing startup, announced a seed round of Rs 12 crore (≈$1.4 million) led by Transition VC. The capital will fund industrial pilots, research expansion, IP filing, and the creation of a US entity to support global market development.
BioReact Secures Undisclosed Investment From University of Tulsa and Hurricane Ventures
BioReact, an Indianapolis‑based AI and analytics platform for bioprocess development, announced an undisclosed investment from the University of Tulsa and Hurricane Ventures. The funding will be used to accelerate go‑to‑market efforts and expand product capabilities. The announcement was made on...
AMPLY Discovery Secures Strategic Investment From Keeps Biomed
AMPLY Discovery, an AI‑driven drug discovery platform based in Belfast, has received a strategic investment from Keeps Biomed, a subsidiary of South Korean biotech Keeps Biopharma. The undisclosed amount will be used to advance oncology research, expand its drug discovery...
Gilead Acquires Global Rights to Genhouse Bio's Oral Cancer Drug for $80M
Gilead announced it will acquire the global rights to an oral cancer drug from China-based biotech Genhouse Bio, paying $80 million upfront. The deal expands Gilead's oncology pipeline as Genhouse prepares for a Hong Kong IPO.
ILiAD Biotechnologies Secures $115M Series B to Advance Whooping Cough Vaccine
ILiAD Biotechnologies announced an oversubscribed $115 million Series B financing on Tuesday. The new capital will fund pivotal Phase 3 trials for its whooping cough vaccine, accelerating development and potential market entry.
Cascade Pharmaceuticals Raises $72M to Develop MASH, Obesity and Diabetes Drugs
Shanghai-based biotech Cascade Pharmaceuticals announced it has secured $72 million (about 500 million yuan) in new funding to advance its pipeline targeting metabolic-associated steatohepatitis (MASH), obesity, and diabetes. The capital will support preclinical and clinical development of its drug candidates.
Eli Lilly to Acquire Orna Therapeutics for $2.4 Billion
Eli Lilly announced it will acquire biotech firm Orna Therapeutics for up to $2.4 billion. Orna's in vivo CAR-T and circular RNA technology targets autoimmune diseases, expanding Lilly's cell-therapy pipeline.
Java Capital Launches Rs 400 Cr Deep‑tech Seed‑stage Fund
Java Capital announced the launch of a Rs 400 crore deep‑tech fund aimed at seed‑stage startups across sectors such as semiconductors, aerospace, defence, cybersecurity, AI infrastructure, robotics, advanced manufacturing, energy, climate tech, and synthetic biology. The fund includes a Rs 150 crore greenshoe option...
Galux Secures $29M Series B Funding Led by Yuanta
South Korean biotech Galux Inc., which uses generative AI for protein and antibody design, announced a $29 million Series B financing led by Yuanta. The fresh capital will support scaling of its AI‑driven biologics platform and recent collaboration with Boehringer Ingelheim. The...
QuantX Biosciences Secures $85M Series B Funding Led by Lilly and Sanofi Ventures
China‑American biotech QuantX Biosciences announced a $85 million Series B round, led by the venture arms of Eli Lilly and Sanofi. The funding will accelerate its immunology pipeline targeting key immune‑related diseases. The round highlights strong investor interest in biotech innovations.
Aerska Raises $39M in Back-to-Back Financing to Advance Brain Gene‑silencing Therapies
Irish‑British biotech Aerska, developing brain‑shuttle technology to deliver siRNA across the blood‑brain barrier, announced a $39 million financing round. The new funding follows a prior raise just four months earlier and will support development of treatments for neurological diseases. Investors were...
Agomab Therapeutics and SpyGlass Pharma Set to IPO on Friday
Fibrosis‑focused Agomab Therapeutics and eye‑disease company SpyGlass Pharma announced they will go public on Friday, marking a significant week for biotech IPOs. The offerings are expected to boost the biotech sector's comeback after a slowdown.
BeHuman Raises $4M Seed Round to Advance Early Cancer Detection
beHuman, a physician-led preventive care platform focused on early cancer detection for underserved populations, announced a $4 million seed round. The funding will support the company's efforts to expand its services and improve early detection capabilities.
Angitia Biopharma Secures $130M Series D to Advance Musculoskeletal Drug Pipeline
US-China biotech Angitia Biopharmaceuticals announced a $130 million Series D financing to support three biologics in clinical testing for musculoskeletal diseases. The funding will advance its pipeline, including a candidate that previously fell short at Ultragenyx, highlighting investor confidence in...
Eikon Therapeutics Announces IPO Amid Valuation Cut
Bay Area biotech startup Eikon Therapeutics is preparing for an initial public offering, shifting from its $1 billion fundraising history. The analysis highlights a significant valuation cut as the company moves toward going public, marking a major event in the biotech...
Veradermics Surges 122% on Debut as Biotech Goes Public
Biotech firm Veradermics, developing an oral form of Rogaine, completed its initial public offering, with its shares jumping 122% on the first day of trading. The strong debut reflects investor enthusiasm for the growing aesthetics market and the company's innovative...
Generate:Biomedicines Files for IPO to Commercialize AI-Driven Drugs
Generate:Biomedicines, a Flagship Pioneering-backed AI bio startup, has filed for an initial public offering just nine days after dosing its first patient in a Phase 3 trial. The filing signals the company’s move to raise capital and bring AI-driven drug...
Imbed Biosciences Secures Undisclosed Investment From BioLab Holdings
Imbed Biosciences, a synthetic antimicrobial and tissue‑regeneration solutions company, announced an undisclosed investment from BioLab Holdings to accelerate development of its SAM Antimicrobial Technology platform for wound‑care. The funding will support product development and commercialization efforts. The deal was reported...
Novartis to Acquire Avidity Biosciences in $12B Takeover
Swiss pharma giant Novartis announced it will acquire RNA‑drug developer Avidity Biosciences for $12 billion, with the transaction expected to close in the next few months. The deal is part of Novartis' strategy to bolster its pipeline amid significant patent expiries,...
PrimeGen US to Merge with DT Cloud Star Acquisition Corp in $1.5B SPAC Deal
California-based biotech PrimeGen US announced a merger with SPAC DT Cloud Star Acquisition Corporation, valuing PrimeGen at approximately $1.5 billion in equity. The transaction, disclosed in a February 4 SEC filing, is expected to close in the second half of 2026 pending...
Stratus Medical Raises $10M in Series B Funding
Stratus Medical, a Magnolia, TX‑based medical device company, announced a $10 million Series B round led by Wasatch Health Partners. The funding will support development of its RF generator and BVNA technology, expand its patent portfolio, and fund a clinical study.
Medtronic to Acquire CathWorks for Up to $585M
Medtronic plc announced it will exercise its option to acquire privately held medical device maker CathWorks for up to $585 million, pending FTC approval. The deal will expand Medtronic’s interventional cardiology portfolio by adding CathWorks’ AI‑driven FFRangio system. Closing is expected...
SonoVascular Secures $6M Series A Funding Led by Harbright Ventures
SonoVascular, a clinical‑stage medical‑device company, announced the first close of its $6 million Series A preferred stock financing, led by Harbright Ventures. The capital will fund FDA approval for a pivotal peripheral venous study and a first‑in‑human trial for pulmonary embolism treatment....
Good Culture Secures $55M Investment From SEMCAP Food & Nutrition and L Catterton
Austin-based cultured dairy brand Good Culture announced a $55 million funding round. The round was led by SEMCAP Food & Nutrition, which joined existing majority investor L Catterton. The capital will fuel growth, accelerate product innovation, and expand distribution across...
Ecovia Bio Secures Series B Funding Led by Pointe Angels
Ecovia Bio, a Michigan-based biotech firm specializing in sustainable biopolymers, announced the closing of a Series B funding round led by Pointe Angels. The capital will be used to expand manufacturing capacity at its Livonia facility to meet rising demand...
Automata Secures $45M Series C Funding Led by Dimension
Automata, a lab automation company, announced the close of a $45 million Series C round led by Dimension, with participation from Danaher Ventures, Tru Arrow Partners, Octopus Ventures, Entrepreneurs First and others. The round also includes a strategic investment partnership...
AstraZeneca Signs $1.2B Upfront Deal with CSPC for Obesity Assets
AstraZeneca announced a partnership with China's CSPC Pharmaceutical Group, paying $1.2 billion upfront for exclusive ex‑China rights to eight obesity and diabetes programs, including the GLP‑1R/GIPR agonist SYH2082. The total deal value is projected at $18.5 billion, marking one of AZ's largest...
Moderna Partners with Recordati on Rare Disease mRNA Therapy in up to $160M Deal
Moderna and Italy’s Recordati announced a partnership to develop and commercialize mRNA‑3927 for propionic acidemia. Recordati will pay up to $160 million in upfront and milestone payments and receive royalties, while Moderna will lead clinical development and manufacturing and Recordati will...
Agomab Therapeutics Targets $182M Nasdaq IPO to Fund Fibrosis Pipeline
Belgian biotech Agomab Therapeutics announced plans for a Nasdaq IPO to raise approximately $182 million in net proceeds. The capital will support the development of its fibrosis drug pipeline, with the company aiming to sell 12.5 million shares. The offering...
Elysium Therapeutics Secures $7.5M SAFE Funding to Accelerate Opioid Overdose Treatment
Elysium Therapeutics, a biopharmaceutical company based in Lyons, Colorado, announced it closed a $7.5 million SAFE round to accelerate development of its Synthetic Opioid Overdose Prevention and Reversal (SOOPR) technology. The funding will support further advancement of its opioid antagonist and...
Eikon Therapeutics Prices IPO, Targets $318M Raise
Eikon Therapeutics, the biotech startup founded by former MSD R&D head Roger Perlmutter, announced pricing of its Nasdaq IPO at $16‑$18 per share, aiming to raise up to $318 million and achieve a valuation above $900 million. The company will list under...
CraniUS Therapeutics Secures $20M Series B Funding to Accelerate NeuroPASS Development
CraniUS Therapeutics, a Baltimore‑based neurotechnology firm, announced a $20 million Series B round, with $19 million from private investors and $1 million non‑dilutive funding from the State of Maryland. The capital will be used to accelerate development of its fully implantable, skull‑embedded platform, NeuroPASS.
Veradermics Targets $181.8M Net Proceeds in Upcoming IPO
Biotech firm Veradermics, developing an oral version of Rogaine, announced plans to go public and raise approximately $181.8 million in net proceeds. The proposed IPO will fund late‑stage testing and commercialization of its hair‑loss treatment.